ReviewFrontiers in immunology2026
Is blood eosinophilia a treatable trait in chronic obstructive airway diseases?
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nowadays, the management of chronic obstructive airway diseases is shifting from traditional diagnostic labels toward a precision medicine approach based on "treatable traits." Among these, blood eosinophilia is emerging as a biomarker of type 2 (T2) inflammation across asthma and chronic obstructive airway diseases (COPD), even if its role as diagnostic tool and therapeutic target remains debated. In this manuscript we presented a clinical case of a 60-year-old male, former mild smoker (5 p/y), initially diagnosed with severe COPD with persistent airflow limitation, frequent severe exacerbations and persistent eosinophilia, but a history of asthma and nasal polyposis. After six months with optimization of inhaled therapy and clinical reassessment, the diagnosis of "severe COPD" shifted to the diagnosis of "severe eosinophilic asthma". Considering the new diagnosis, he was prescribed mepolizumab on top of triple inhaled therapy. After 1 year, the clinical response was excellent in terms of symptoms control, exacerbations reduction and OCS sparing, despite no improvement in lung function. Starting from this clinical case, the aim of this mini review is to describe the role of eosinophilic inflammation in asthma and COPD. While eosinophilic inflammation is a common feature of asthma, COPD is usually characterized by neutrophilic inflammation, even if, a subset of patients with COPD has eosinophilic inflammation. In this context, blood eosinophilia might represent a clinically actionable trait to guide diagnosis and personalized therapy in chronic airway diseases even if it should not be targeted in isolation but be integrated into a multidimensional assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.